2021
Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer
Datar IJ, Hauc SC, Desai S, Gianino N, Henick B, Liu Y, Syrigos K, Rimm DL, Kavathas P, Ferrone S, Schalper KA. Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer. Clinical Cancer Research 2021, 27: 2837-2847. PMID: 33602682, PMCID: PMC8734284, DOI: 10.1158/1078-0432.ccr-20-3655.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNK cell infiltrationReduced T cellCell lung cancerHLA class IIT cellsLung cancerHLA classClinical significanceSubunit expressionHLA class II downregulationΒ2MClass IIHLA genesHuman leukocyte antigen classShorter overall survivalTumor microenvironment compositionClass II β chainImmune contextureOverall survivalLung malignancyNatural killerPatient survivalCell infiltrationClinicopathologic variables
2018
Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).
Datar I, Villarroel-Espindola F, Henick B, Syrigos K, Toki M, Rimm D, Ferrone S, Herbst R, Schalper K. Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2018, 36: 12015-12015. DOI: 10.1200/jco.2018.36.15_suppl.12015.Peer-Reviewed Original Research
2017
Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, Brown J, Lannin D, Pusztai L, Rimm DL. Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Research 2017, 19: 109. PMID: 28946899, PMCID: PMC5613519, DOI: 10.1186/s13058-017-0898-2.Peer-Reviewed Original ResearchObjective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance
Carvajal-Hausdorf DE, Schalper KA, Bai Y, Black J, Santin AD, Rimm DL. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. Gynecologic Oncology 2017, 145: 154-158. PMID: 28196634, PMCID: PMC5941302, DOI: 10.1016/j.ygyno.2017.02.002.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAfatinibAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCohort StudiesExtracellular SpaceFemaleFluorescent Antibody TechniqueHumansIntracellular SpaceLapatinibMaytansineMiddle AgedNeoplasms, Cystic, Mucinous, and SerousOvarian NeoplasmsProtein DomainsQuinazolinesReceptor, ErbB-2Retrospective StudiesTissue Array AnalysisTrastuzumabUterine NeoplasmsConceptsUterine serous carcinomaOvarian serous carcinomaHER2 intracellular domainSerous carcinomaECD levelsECD statusTissue microarrayHER2 measurementQuantitative immunofluorescenceHER2 overexpression/amplificationClinico-pathologic characteristicsClinico-pathological featuresHER2-targeted agentsIntracellular domainOverexpression/amplificationHER2 extracellular domainExtracellular domainOSC patientsClinical trialsBreast cancerClinical significancePatientsHER2 assaysP95-HER2Carcinoma
2009
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings Of The National Academy Of Sciences Of The United States Of America 2009, 106: 13820-13825. PMID: 19666588, PMCID: PMC2720409, DOI: 10.1073/pnas.0905718106.Peer-Reviewed Original ResearchConceptsBreast cancerConventional treatmentHigh tumor-initiating potentialResidual breast cancerBreast cancer patientsCell surface antigen profileLong-term survivalHuman breast tumorsBreast cancer cellsTumor-initiating cellsTumor-initiating potentialEndocrine therapyGene expression signaturesCancer patientsTumor cell populationClinical significanceMolecular subtypesTherapeutic strategiesMesenchymal markersMetalloproteinase-2Breast tumorsSubpopulation of cellsAntigen profileMesenchymal featuresTumor tissue
2008
Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-in-Pentetreotide. Addendum
Chung G, Rimm D. Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-in-Pentetreotide. Addendum. 2008 DOI: 10.21236/ada487987.Peer-Reviewed Original ResearchBreast cancerTissue microarrayPredominant receptor subtypeWhole section analysisBenign breast tissueHeterogeneity of expressionSSTR2 levelsProgression of cancerTargeted therapyReceptor subtypesSomatostatin receptorsClinical significanceLymphatic elementsCo-localization techniquesCell line controlMalignant cellsSSTR2Breast tissueCancerPattern of expressionProtein expressionPeptide hormonesVessel compartmentReference standard curveSomatostatin
2006
Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy With 111-in-Penetreotide
Chung G, Murren J, Rimm D. Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy With 111-in-Penetreotide. 2006 DOI: 10.21236/ada455786.Peer-Reviewed Original ResearchBreast cancerTissue microarrayPredominant receptor subtypeBenign breast tissueSSTR2 levelsProgression of cancerSSTR2 expressionBone tumorsTargeted therapyReceptor subtypesSomatostatin receptorsClinical significanceCo-localization techniquesCell line controlMalignant cellsCancerBreast tissuePattern of expressionProtein expressionPeptide hormonesSomatostatinSSTR2ExpressionLarge proportionTherapy
2003
Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.
Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Research 2003, 63: 8103-7. PMID: 14678960.Peer-Reviewed Original ResearchConceptsATF2 expressionTranscription factor 2Melanoma specimensUseful prognostic markerEarly-stage melanomaWeak cytoplasmic stainingStrong nuclear stainingFactor 2Mean followCutaneous specimensLocalized diseaseOverall survivalIndependent predictorsPreclinical findingsClark levelClinicopathological dataPatient survivalPoor outcomePrognostic valueWorse outcomesPrognostic markerPoor survivalPreclinical modelsClinical significanceImmunohistochemical staining